russjcardiolРоссийский кардиологический журналRussian Journal of Cardiology1560-40712618-7620«SILICEA-POLIGRAF» LLC10.15829/1560-4071-2014-11-76-82russjcardiol-153Research ArticleОБЗОРЫ ЛИТЕРАТУРЫREVIEWСОВРЕМЕННЫЕ ПРЕДСТАВЛЕНИЯ О ПЕРИПАРТАЛЬНОЙ КАРДИОМИОПАТИИ — ОПРЕДЕЛЕНИЕ, ЭПИДЕМИОЛОГИЯ, ПАТОГЕНЕЗ (ЧАСТЬ I)CONTEMPORARY VIEWS ON PERIPARTUM CARDIOMYOPATHY — DEFINITION, EPIDEMIOLOGY, PATHOGENESIS (PART I)ВатутинН. Т.VatutinN. T.

Доктор медицинских наук, профессор, заведующий кафедрой внутренней медицины №1

taradin@inbox.ruТарадинГ. Г.TaradinG. G.

Кандидат медицинских наук доцент кафедры внутренней медицины №1

taradin@inbox.ruКорниенкоС. М.KornienkoS. M.

Кандидат медицинских наук доцент кафедры акушерства, гинекологии и перинатологии ФИПО

taradin@inbox.ruТараторинаА. А.TaratorinaA. A.

Студентка 6 курса

taradin@inbox.ruКетингЕ. В.KetingE. V.

Кандидат медицинских наук доцент кафедры внутренней медицины №1

taradin@inbox.ruДонецкий национальный медицинский университет имени М. Горького, ДонецкУкраинаDonetsk National Medical University n.a. M. Gorky, DonetskUkraine2014281120140117682Copyright © Ватутин Н.Т., Тарадин Г.Г., Корниенко С.М., Тараторина А.А., Кетинг Е.В., 20142014Ватутин Н.Т., Тарадин Г.Г., Корниенко С.М., Тараторина А.А., Кетинг Е.В.Vatutin N.T., Taradin G.G., Kornienko S.M., Taratorina A.A., Keting E.V.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://russjcardiol.elpub.ru/jour/article/view/153

В первой части обзора, посвященного перипартальной кардиомиопатии, обсуждаются вопросы определения заболевания, его распространенности по данным различных эпидемиологических исследований, проведенных в различных странах. Подробное внимание уделено факторам риска заболевания, в частности возрастному акушерскому анамнезу, беременностью двойней и более, токололитической терапии, курению, артериальной гипертензии и др. Обсуждаются сложные вопросы этиопатогенеза заболевания, включая миокардит, роль системы пролактин-катепсин-пролактин 16 кDa, нарушение питания, дефицит селена, генетическую предрасположенность на фоне патологического ответа на гемодинамический стресс во время беременности.

The first part of the review of peripartum cardiomyopathy concerns on the disease itself, its prevalence by the data from various epidemiologic studies in different countries. More detailed the risk factors are discussed, especially age-related obstetrics anamnesis, double pregnancy or more, tocolytic therapy, smoking, arterial hypertension etc. Complicated questions of the etiopathogensis are discussed, including myocarditis, the role of prolactine-catepsine-prolactie 16kDa system, nutrition disorders, selenium deficiency, genetic predisposition at the background of pathologic response on hemodynamic stress during pregnancy.

перипартальная кардиомиопатияопределениеэпидемиологияфакторы рискапатогенезпролактинperipartum cardiomyopathydefinitionepidemiologyrisk factorspathogenesisprolactineReferencesLewis GE. Saving mothers’ lives: reviewing maternal deaths to make motherhood safer: 2006–2008. The Eighth Report of the Confidential Enquiries into Maternal Deaths in the United Kingdom. BJOG. 2011; 118: 1-203.Lewis GE. Saving mothers’ lives: reviewing maternal deaths to make motherhood safer: 2006–2008. The Eighth Report of the Confidential Enquiries into Maternal Deaths in the United Kingdom. BJOG. 2011; 118: 1-203.Huisman CM, Zwart JJ, Roos-Hesselink JW, et al. Incidence and predictors of maternal cardiovascular mortality in the Netherlands: a prospective cohort study. PLoS ONE. 2013; 8: e56494. doi:10.1371/journal.pone.0056494.Huisman CM, Zwart JJ, Roos-Hesselink JW, et al. Incidence and predictors of maternal cardiovascular mortality in the Netherlands: a prospective cohort study. PLoS ONE. 2013; 8: e56494. doi:10.1371/journal.pone.0056494.Roos-Hesselink JW, Duvekot JJ, Thorne SA. Pregnancy in high risk cardiac conditions. Heart. 2009; 95: 680-6. doi: 10.1136/hrt.2008.148932.Roos-Hesselink JW, Duvekot JJ, Thorne SA. Pregnancy in high risk cardiac conditions. Heart. 2009; 95: 680-6. doi: 10.1136/hrt.2008.148932.Gelson E, Gatzoulis M, Steer P, et al. Heart disease — why is maternal mortality increasing? BJOG. 2009; 116: 609–611. doi: 10.1111/j.1471-0528.2008.02082.x.Gelson E, Gatzoulis M, Steer P, et al. Heart disease — why is maternal mortality increasing? BJOG. 2009; 116: 609–611. doi: 10.1111/j.1471-0528.2008.02082.x.Berg CJ, Chang J, Callaghan WM, et al. Pregnancy-related mortality in the United States, 1998 to 2005. Obstet. Gynecol. 2010; 116: 1302-9.Berg CJ, Chang J, Callaghan WM, et al. Pregnancy-related mortality in the United States, 1998 to 2005. Obstet. Gynecol. 2010; 116: 1302-9.Schutte JM, Steegers EA, Schuitemaker NW, et al. Rise in maternal mortality in the Netherlands. BJOG. 2010; 117: 399-406. doi: 10.1111/j.1471-0528.2009.02382.x.Schutte JM, Steegers EA, Schuitemaker NW, et al. Rise in maternal mortality in the Netherlands. BJOG. 2010; 117: 399-406. doi: 10.1111/j.1471-0528.2009.02382.x.Esscher A, Högberg U, Haglund B, et al. Maternal mortality in Sweden 1988–2007: more deaths than officially reported. Acta Obstet. Gynecol. Scand. 2013; 92: 40-6. doi: 10.1111/ aogs.12037.Esscher A, Högberg U, Haglund B, et al. Maternal mortality in Sweden 1988–2007: more deaths than officially reported. Acta Obstet. Gynecol. Scand. 2013; 92: 40-6. doi: 10.1111/ aogs.12037.Johnson-Coyle L, Jensen L, Sobey A. Peripartum cardiomyopathy: review and practice guidelines. Amer. J. Crit. Care. 2012; 21: 89-98. doi: 10.4037/ajcc2012163Johnson-Coyle L, Jensen L, Sobey A. Peripartum cardiomyopathy: review and practice guidelines. Amer. J. Crit. Care. 2012; 21: 89-98. doi: 10.4037/ajcc2012163Sliwa K, Hilfiker-Kleiner D, Petrie MC, et al. Current state of knowledge on aetiology, diagnosis, management, and therapy of peripartum cardiomyopathy: a position statement from Heart Failure Association of European Society of Cardiology Working Group on peripartum cardiomyopathy. Eur. J. Heart Failure. 2010; 12: 767-78.Sliwa K, Hilfiker-Kleiner D, Petrie MC, et al. Current state of knowledge on aetiology, diagnosis, management, and therapy of peripartum cardiomyopathy: a position statement from Heart Failure Association of European Society of Cardiology Working Group on peripartum cardiomyopathy. Eur. J. Heart Failure. 2010; 12: 767-78.Pearson GD, Veille JC, Rahimtoola S, et al. Peripartum cardiomyopathy: National Heart, Lung, and Blood Institute and Office of Rare Diseases (National Institutes of Health) workshop recommendations and review. JAMA 2000; 283: 1183-8.Pearson GD, Veille JC, Rahimtoola S, et al. Peripartum cardiomyopathy: National Heart, Lung, and Blood Institute and Office of Rare Diseases (National Institutes of Health) workshop recommendations and review. JAMA 2000; 283: 1183-8.Медведь В. И., Давыдова Ю. В. Перипартальная кардиомиопатия как бидисциплинарная проблема. Серцева недостатнiсть. 2011; 1: 94-7.Медведь В. И., Давыдова Ю. В. Перипартальная кардиомиопатия как бидисциплинарная проблема. Серцева недостатнiсть. 2011; 1: 94-7.Elkayam U, Akhter M.W, Singh H, et al. Pregnancy-associated cardiomyopathy. Clinical characteristics and a comparison between early and late presentation. Circulation. 2005; 111: 2050-5.Elkayam U, Akhter M.W, Singh H, et al. Pregnancy-associated cardiomyopathy. Clinical characteristics and a comparison between early and late presentation. Circulation. 2005; 111: 2050-5.Richie C. Clinical contribution to the pathology, diagnosis and treatment of certain chronic diseases of the heart. Edinb. Med. Surg. J. 1849; 2: 333-42.Richie C. Clinical contribution to the pathology, diagnosis and treatment of certain chronic diseases of the heart. Edinb. Med. Surg. J. 1849; 2: 333-42.Gouley BA, McMillan TM, Bellet S. Idiopathic myocardial degeneration associated with pregnancy and especially the puerperium. Amer. J. Med. Scien. 1937; 19: 185-99.Gouley BA, McMillan TM, Bellet S. Idiopathic myocardial degeneration associated with pregnancy and especially the puerperium. Amer. J. Med. Scien. 1937; 19: 185-99.Hull E, Hafkesbring E. “Toxic” postpartum heart disease. New Orleans Med. Surg. J. 1937; 89: 550.Hull E, Hafkesbring E. “Toxic” postpartum heart disease. New Orleans Med. Surg. J. 1937; 89: 550.Mishra VN, Mishra N, Devanshi. Peripartum cardiomyopathy. JAPI. 2013; 61; 268-73.Mishra VN, Mishra N, Devanshi. Peripartum cardiomyopathy. JAPI. 2013; 61; 268-73.Okeke TC, Ezenyeaku CCT, Ikeako LC. Peripartum cardiomyopathy. Ann. Med. Health Sci. Res. 2013; 3(3): 313-9.Okeke TC, Ezenyeaku CCT, Ikeako LC. Peripartum cardiomyopathy. Ann. Med. Health Sci. Res. 2013; 3(3): 313-9.Blauwet LA, Cooper LT. Diagnosis and management of peripartum cardiomyopathy. Heart. 2011; 97: 1970-1981. doi: 10.1136/heartjnl-2011-300349.Blauwet LA, Cooper LT. Diagnosis and management of peripartum cardiomyopathy. Heart. 2011; 97: 1970-1981. doi: 10.1136/heartjnl-2011-300349.Pyatt JR, Dubey G. Peripartum cardiomyopathy: current understanding, comprehensive management review and new developments. Postgrad. Med. J. 2010; 87: 34-9.Pyatt JR, Dubey G. Peripartum cardiomyopathy: current understanding, comprehensive management review and new developments. Postgrad. Med. J. 2010; 87: 34-9.Bhattacharyya A, Basra SS, Sen P, et al. Peripartum cardiomyopathy: a review. Tex. Heart Inst. J. 2012; 39(1): 8-16.Bhattacharyya A, Basra SS, Sen P, et al. Peripartum cardiomyopathy: a review. Tex. Heart Inst. J. 2012; 39(1): 8-16.Zhang F. The research into the clinical characteristics of peripartum cardiomyopathy. Heart. 2012; 98: 165-6. doi:10.1136/heartjnl-2012-302920j.17Zhang F. The research into the clinical characteristics of peripartum cardiomyopathy. Heart. 2012; 98: 165-6. doi:10.1136/heartjnl-2012-302920j.17Lok SI, Kirkels JH, Klöpping C, et al. Peripartum cardiomyopathy: the need for a national database. Neth. Heart J. 2011; doi 10.1007/s12471-011-0083-7.Lok SI, Kirkels JH, Klöpping C, et al. Peripartum cardiomyopathy: the need for a national database. Neth. Heart J. 2011; doi 10.1007/s12471-011-0083-7.Givertz MM. Peripartum cardiomyopathy. Circulation. 2013; 127: e622-e626. doi:10.1161/ CIRCULATIONAHA. 113.001851.Givertz MM. Peripartum cardiomyopathy. Circulation. 2013; 127: e622-e626. doi:10.1161/ CIRCULATIONAHA. 113.001851.Gunderson EP, Croen LA, Chiang V, et al. Epidemiology of peripartum cardiomyopathy. 2011; 118 (3): 583-591. doi: 10.1097/AOG.0b013e318229e6de.Gunderson EP, Croen LA, Chiang V, et al. Epidemiology of peripartum cardiomyopathy. 2011; 118 (3): 583-591. doi: 10.1097/AOG.0b013e318229e6de.Sliwa K, Föster O, Libhaber E, et al. Peripartum cardiomyopathy: inflammatory markers as predictors of outcome in 100 prospectively studied patients. Eur. Heart J. 2006; 27: 441-6.Sliwa K, Föster O, Libhaber E, et al. Peripartum cardiomyopathy: inflammatory markers as predictors of outcome in 100 prospectively studied patients. Eur. Heart J. 2006; 27: 441-6.Lapaire O, Hosli I, Zanetti-Daellenbach R, et al. Impact of fetal-maternal microchimerism on women’s health a review. J. Matern. Fetal Neonatal. Med. 2007; 20(1): 1-5.Lapaire O, Hosli I, Zanetti-Daellenbach R, et al. Impact of fetal-maternal microchimerism on women’s health a review. J. Matern. Fetal Neonatal. Med. 2007; 20(1): 1-5.Lamparter S, Pankuweit S, Maisch B. Clinical and immunological characteristics in peripartum cardiomyopathy. Int. J. Cardiol. 2007; 118: 14-20.Lamparter S, Pankuweit S, Maisch B. Clinical and immunological characteristics in peripartum cardiomyopathy. Int. J. Cardiol. 2007; 118: 14-20.Warraich RS, Sliwa K, Damasceno A, et al. Impact of pregnancy-related heart failure on humoral immunity: clinical relevance of G3-subclass immunoglobulins in peripartum cardiomyopathy. Amer. Heart J. 2005; 150: 263-9.Warraich RS, Sliwa K, Damasceno A, et al. Impact of pregnancy-related heart failure on humoral immunity: clinical relevance of G3-subclass immunoglobulins in peripartum cardiomyopathy. Amer. Heart J. 2005; 150: 263-9.Bultmann BD, Klingel K, Nabauer M, et al. High prevalence of viral genomes and inflammation in peripartum cardiomyopathy. Amer. J. Obstet. Gynecol. 2005; 193: 363-5.Bultmann BD, Klingel K, Nabauer M, et al. High prevalence of viral genomes and inflammation in peripartum cardiomyopathy. Amer. J. Obstet. Gynecol. 2005; 193: 363-5.Fett JD. Viral infection as a possible trigger for the development of peripartum cardiomyopathy. Int. J. Gynaecol. Obstet. 2007; 97: 149-50.Fett JD. Viral infection as a possible trigger for the development of peripartum cardiomyopathy. Int. J. Gynaecol. Obstet. 2007; 97: 149-50.Hilfiker-Kleiner D, Sliwa K, Drexler H. Peripartum cardiomyopathy: into recent insight its pathophysiology. Trends Cardiovasc. Med. 2008; 18: 173-9.Hilfiker-Kleiner D, Sliwa K, Drexler H. Peripartum cardiomyopathy: into recent insight its pathophysiology. Trends Cardiovasc. Med. 2008; 18: 173-9.Hilfiker-Kleiner D, Meyer GP, Schieffer E, et al. Recovery from postpartum cardiomyopathy in 2 patients by blocking prolactin release with bromocriptine. J. Amer. Coll. Cardiol. 2007; 50; 2354-5.Hilfiker-Kleiner D, Meyer GP, Schieffer E, et al. Recovery from postpartum cardiomyopathy in 2 patients by blocking prolactin release with bromocriptine. J. Amer. Coll. Cardiol. 2007; 50; 2354-5.Hilfiker-Kleiner D, Kaminski K, Podewski E, et al. A cathepsin derived 16kDa form of prolactin mediates postpartum cardiomyopathy. Cell. 2007; 128: 589-600.Hilfiker-Kleiner D, Kaminski K, Podewski E, et al. A cathepsin derived 16kDa form of prolactin mediates postpartum cardiomyopathy. Cell. 2007; 128: 589-600.Yamac H, Bultmann I, Sliwa K, et al. Prolactin: a new therapeutic target in peripartum cardiomyopathy. Heart. 2010; 96: 1352-7.Yamac H, Bultmann I, Sliwa K, et al. Prolactin: a new therapeutic target in peripartum cardiomyopathy. Heart. 2010; 96: 1352-7.Habedank D, Kuhenle Y, Elgeti T, et al. Recovery from peripartum cardiomyopathy after treatment with bromocriptine. Eur. J. Heart Failure. 2008; 10: 1149-51.Habedank D, Kuhenle Y, Elgeti T, et al. Recovery from peripartum cardiomyopathy after treatment with bromocriptine. Eur. J. Heart Failure. 2008; 10: 1149-51.De Jong JS, Rietveld K, Van Lochem LT, et al. Rapid left ventricular recovery after cabergoline treatment in a patient with peripartum cardiomyopathy. Eur. J. Heart Failure. 2009; 11: 220-2.De Jong JS, Rietveld K, Van Lochem LT, et al. Rapid left ventricular recovery after cabergoline treatment in a patient with peripartum cardiomyopathy. Eur. J. Heart Failure. 2009; 11: 220-2.Halkein J, Tabruyn SP, Ricke-Hoch M, et al. MicroRNA-146a is a therapeutic target and biomarker for peripartum cardiomyopathy. J. Clin. Invest. 2013; 123(5): 2143-54. doi:10.1172/JCI64365.Halkein J, Tabruyn SP, Ricke-Hoch M, et al. MicroRNA-146a is a therapeutic target and biomarker for peripartum cardiomyopathy. J. Clin. Invest. 2013; 123(5): 2143-54. doi:10.1172/JCI64365.Walenta K, Schwarz V, Schrimer SH, et al. Circulating microparticles as indicators of peripartum cardiomyopathy. Eur. Heart J. 2012; 33(12): 1469-79. doi: 10.1093/eurheartj/ehr485.Walenta K, Schwarz V, Schrimer SH, et al. Circulating microparticles as indicators of peripartum cardiomyopathy. Eur. Heart J. 2012; 33(12): 1469-79. doi: 10.1093/eurheartj/ehr485.Wu Z-H, Ji C-L, Li H, et al. Membrane microparticles and diseases. Eur. Rev. Med. Pharm. Scien. 2013; 17: 2420-7.Wu Z-H, Ji C-L, Li H, et al. Membrane microparticles and diseases. Eur. Rev. Med. Pharm. Scien. 2013; 17: 2420-7.Fett JD, Sundstrom JB, Etta King M, et al.Mother-daughter peripartum cardiomyopathy. Inter. J. Cardiol. 2002; 86: 331-2.Fett JD, Sundstrom JB, Etta King M, et al.Mother-daughter peripartum cardiomyopathy. Inter. J. Cardiol. 2002; 86: 331-2.Meyer GP, Labidi S, Podewski E, et al. Bromocriptine treatment associated with recovery from peripartum cardiomyopathy in siblings: two case reports. J. Med. Case Reports. 2010; 4: 80.Meyer GP, Labidi S, Podewski E, et al. Bromocriptine treatment associated with recovery from peripartum cardiomyopathy in siblings: two case reports. J. Med. Case Reports. 2010; 4: 80.Van Spaendock-Zwarts KY, van Tintelen JP, van Veldhuisen DJ, et al. Peripartum cardiomyopathy as a part of familial dilated cardiomyopathy. Circulation. 2010; 121: 2169-75.Van Spaendock-Zwarts KY, van Tintelen JP, van Veldhuisen DJ, et al. Peripartum cardiomyopathy as a part of familial dilated cardiomyopathy. Circulation. 2010; 121: 2169-75.Morales A, Painter T, Li R, et al. Rare variant mutations in pregnancy-associated or peripartum cardiomyopathy. Circulation. 2010; 121: 2176-82.Morales A, Painter T, Li R, et al. Rare variant mutations in pregnancy-associated or peripartum cardiomyopathy. Circulation. 2010; 121: 2176-82.Karamermer Y, Roos-Hesselink JW. Pregnancy and adult congenital heart disease. Expert Rev. Cardiovasc. Ther. 2007; 5: 859-69.Karamermer Y, Roos-Hesselink JW. Pregnancy and adult congenital heart disease. Expert Rev. Cardiovasc. Ther. 2007; 5: 859-69.Geva T, Mauer MB, Striker L, et al. Effects of physiologic load of pregnancy on left ventricular contractility and remodeling. Amer. Heart J 1997; 133: 53-9.Geva T, Mauer MB, Striker L, et al. Effects of physiologic load of pregnancy on left ventricular contractility and remodeling. Amer. Heart J 1997; 133: 53-9.Cénac A, Simonoff M, Moretto P, et al. A low plasma selenium is a risk factor for peripartum cardiomyopathy: a comparative study in Sahelian Africa. Int. J Cardiol. 1992; 36(1): 57-9.Cénac A, Simonoff M, Moretto P, et al. A low plasma selenium is a risk factor for peripartum cardiomyopathy: a comparative study in Sahelian Africa. Int. J Cardiol. 1992; 36(1): 57-9.Fett J, Ansara A, Sundstrom J, et al. Peripartum cardiomyopathy: a selenium disconnection and an autoimmune connection. Int. J Cardiol. 2002; 86(2): 311-6.Fett J, Ansara A, Sundstrom J, et al. Peripartum cardiomyopathy: a selenium disconnection and an autoimmune connection. Int. J Cardiol. 2002; 86(2): 311-6.Ntusi NB, Mayosi BM. Aetiology and risk factors of peripartum cardiomyopathy: a systematic review. Int J Cardiol. 2009; 131(2): 168-79.Ntusi NB, Mayosi BM. Aetiology and risk factors of peripartum cardiomyopathy: a systematic review. Int J Cardiol. 2009; 131(2): 168-79.Schleußner E. The prevention, diagnosis and treatment of premature labor. Dtsch. Arztebl. Int. 2013; 110(13): 227-36.Schleußner E. The prevention, diagnosis and treatment of premature labor. Dtsch. Arztebl. Int. 2013; 110(13): 227-36.

The authors declare that there are no conflicts of interest present.